US-based molecular diagnostics company Myriad Genetics has acquired breast cancer prognostic company, Sividon Diagnostics in a deal valued at €50m.

The transaction was done for €35m with a potential additional investment of €15m conditioned on achieving performance-based milestones.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Myriad is planning to fund the transaction on an all-cash basis and expects that the transaction will cast no effect on the company’s revenue and earnings in fiscal year 2017.

"The EndoPredict test will be the foundational product of our newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide."

The transaction has added to Myriad’s portfolio of oncological devices, such as Sividon’s EndoPredict test which is a kit-based RNA expression test measuring the gravity of breast cancer on a molecular level and assists the patients to decide whether to avoid chemotherapy.

Myriad is planning to integrate the product on their Thermo Fisher QuantStudio platform which is currently CE Marked on the Siemens Versant instrument.

Myriad Genetic Laboratories president and CEO Mark Capone said: "The EndoPredict test will be the foundational product of our newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company seeks to increase the market footprint of EndoPredict which they project is greater than $600m with its majority existing in European countries, Canada, and the US.

About 4,000 patients have been subjected to the EndoPredict test and used by more than 13,000 patients exhibiting the product’s ability to determine which patients are at low risk for distant metastases in both node negative and node positive patients.